Every article, presentation, spotlight, and news item we've tagged to Testing and Diagnostics.
Showing 97–120 of 163
TMRW, an Australian longevity platform, secured $7 million in seed funding to expand clinical services and deepen biological age assessment through epigenetic testing in partnership with TruDiagnostic. The company differentiates itself by analyzing approximately 1,700 biological data points and integrating clinical support alongside diagnostics, moving beyond dashboard-only models.
A $6.2 million NIH grant funds AI-driven analysis of 1,800 Alzheimer's-linked genes to identify genetic targets upstream of amyloid pathology, shifting focus from symptomatic treatment to early-stage vulnerability. Current amyloid-targeting drugs slow progression at best; identifying genetic determinants of susceptibility may enable earlier, more precise intervention before neurodegeneration becomes symptomatic.
Sky Labs received UK regulatory approval for CART PLATFORM, a cuffless ring-based blood pressure monitor that integrates wearable hardware, mobile app, and cloud analytics. The authorization enables prescription distribution through UK pharmacies and hospitals, establishing clinical-grade continuous blood pressure monitoring as an accessible diagnostic tool.
Higher diet quality correlates with slower epigenetic aging and reduced mortality risk in two large U.S. cohorts, with epigenetic age acceleration (GrimAgeEAA) explaining approximately 44% of the diet-mortality association in one cohort. The relationship is partially confounded by physical activity and integrated lifestyle factors, indicating that diet operates within a broader system of behavioral and biological aging pathways rather than in isolation.
A single-cell chromatin atlas across 21 tissues reveals that aging involves coordinated, sex-specific regulatory remodeling rather than random molecular decay. The coordinated shifts across anatomically distinct organs suggest systemic drivers—circulating signals, immune tone, endocrine cues—offering both mechanistic insight and practical constraints for intervention design.
Machine learning models trained on routine clinic data predict individual rates of cognitive and functional decline in Alzheimer's disease and mild cognitive impairment with greater accuracy than population averages. Early identification of specific functional vulnerabilities—such as difficulty with finances or meal preparation—enables targeted interventions before independence is lost.
A 4-week dietary intervention in adults aged 65–75 reduced KDM-derived biological age estimates, with the greatest effects seen in high-carbohydrate and semi-vegetarian groups. This rapid shift in composite biomarkers suggests diet produces measurable physiological changes relevant to aging trajectories, though longer-term data are needed to establish impact on disease risk.
Phosphoenolpyruvate, a glycolytic metabolite, suppresses cGAS-driven inflammation through a direct molecular interaction. The age-related decline in PEP availability explains the transition from metabolic stability to chronic inflammation and neurodegeneration.
Researchers identified HCCaging, a transcriptome-based biomarker that reflects liver aging patterns and improves hepatocellular carcinoma diagnosis. This tool bridges the gap between cellular aging processes and cancer risk stratification, offering earlier detection potential before advanced disease.
Human Longevity has released an AI-powered mobile app that analyzes biometric, lifestyle, and genetic data to generate personalized health recommendations across nutrition, exercise, sleep, and preventive care. The platform's utility depends on the quality of data interpretation and user adherence to recommendations over time.
Roche has obtained CE mark approval for a blood test that identifies ApoE4 carriers, a genetic variant associated with increased Alzheimer's risk. This test streamlines risk stratification and treatment planning by enabling clinicians to prioritize patients for further evaluation and guide therapeutic decisions, particularly regarding amyloid-targeting therapies that carry differential risk profiles based on ApoE4 status.
Retinal protein signatures correlate with systemic aging markers and clinical traits in women, establishing the eye as a window into whole-body physiological age. These oculometric measures may enable earlier detection of aging-related dysfunction across multiple organ systems.
Childhood adversity associates with accelerated biological aging markers primarily in women, while adulthood adversity shows stronger associations with aging markers in men. This sex-specific pattern suggests distinct windows of physiological vulnerability across the lifespan that warrant consideration in aging research and clinical intervention timing.
Deep learning analysis of histological and transcriptomic data from over 300 female donors reveals that reproductive organs age asynchronously rather than in lockstep, with menopause functioning as a critical inflection point detectable in circulating protein signatures. This challenges the assumption of synchronized aging across organ systems and identifies tissue-specific vulnerability windows relevant to longevity and disease prevention.
Clair Health has launched a non-invasive wearable that uses multimodal biosensors and AI to infer continuous hormonal patterns across the female lifespan, moving beyond episodic blood tests and calendar-based tracking. The device collects skin temperature, heart rate variability, sleep, and breathing data as proxies for endocrine state, positioning hormonal monitoring as a prevention tool rather than a fertility marker.
Accelerated brain aging—measured as the difference between chronological age and brain imaging markers—correlates with lower bone mineral density and increased fracture risk independent of chronological age. This suggests neurobiological aging patterns may predict skeletal fragility and fracture vulnerability in midlife and older adults.
Telomir-1 (Telomir-Zn) modulates intracellular metal balance by increasing zinc and reducing iron, influencing epigenetic regulation and cellular stability without triggering cytotoxic stress. This mechanism addresses oxidative stress and genomic integrity pathways implicated in aging and cancer biology.
Microglia—the brain's resident immune cells—exhibit distinct transcriptional patterns and morphological changes with age, with subcellular mRNA localization directly influencing their functional capacity. This work establishes how aging alters the molecular foundation of neuroinflammation, a process central to cognitive decline and neurodegenerative disease progression.
Agentis Longevity and Ultrahuman have integrated continuous glucose monitoring and wearable biomarker data into a clinical scoring system (Longevity Quotient) designed to bridge the gap between real-time metabolic data and actionable preventive care. The partnership addresses low engagement in preventive health practices by making personalized, data-driven interventions accessible at scale.
Wearable devices tracking activity rhythms reveal that irregular movement patterns correlate with systemic inflammation and accelerated biological aging. This connection between circadian disruption and aging rate offers a quantifiable marker for longevity risk that precedes clinical disease.
Phosphoenolpyruvate, a glycolytic metabolite, suppresses cGAS-STING-driven inflammation and improves cognitive function in Alzheimer's disease models while correlating with healthy aging markers in humans. This identifies a metabolic checkpoint that regulates innate immune signaling during aging.
QuantalX Neuroscience has launched Delphi MD, an FDA-cleared non-invasive system that quantifies real-time functional brain network activity using transcranial magnetic stimulation, electroencephalography, and AI analytics. This technology enables clinicians to detect subtle changes in brain function before structural damage or cognitive decline becomes apparent, shifting neurological care from reactive symptom management to preventive assessment.
Vascular age acceleration, measured through a quantitative model, independently predicts cardiovascular disease risk beyond chronological age, with a 21–25% increased risk in those showing accelerated vascular aging. This metric enables earlier identification of individuals requiring intervention before overt disease manifestation.
A 20-year follow-up of the ACTIVE trial found that speed-of-processing training with booster sessions reduced dementia diagnoses in older adults, a rare signal of efficacy in prevention research anchored to clinical diagnoses rather than cognitive test scores alone.
